Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

@inproceedings{Strumberg2012Regorafenib7,
  title={Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study},
  author={Dirk Strumberg and Max Ernst Scheulen and Beate S Schultheis and Heike Richly and Annette Frost and Martin Buechert and O. E. Christensen and Michael E. Jeffers and Roland Heinig and Oliver Boix and K. Mross},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC).Methods:Patients received oral regorafenib 60–220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment. Assessments included toxicity, response, pharmacokinetics and pharmacodynamics.Results:Thirty-eight patients with heavily pretreated… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 83 extracted citations

Drug monographs: bosutinib and regorafenib.

Hospital pharmacy • 2013
View 6 Excerpts
Highly Influenced

Regorafenib for treatment of advanced gastrointestinal stromal tumors.

Expert opinion on pharmacotherapy • 2014
View 9 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Evolving treatment of advanced colorectal cancer.

Current oncology reports • 2010
View 4 Excerpts
Highly Influenced

Phase II trial of the oral multikinase inhibitor regorafenib ( BAY 73 - 4506 ) as first - line therapy in patients with metastatic or unresectable renal cell cancer ( RCC )

T Eisen, H Joensuu, +7 authors D Quinn
Eur J Cancer • 2011
View 1 Excerpt

Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell cancer

T Eisen, H Joensuu, +7 authors D Quinn
(RCC) Eur J Cancer 47(Suppl): Abstract • 2011
View 1 Excerpt

Lower Gastrointestinal Tract Cancer Predisposition Syndromes

Hematology/oncology clinics of North America • 2010
View 1 Excerpt

Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites

D Zopf, R Heinig, +6 authors M Radtke
At the American Association for Cancer Research 101st Annual Meeting, • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…